Lead Product(s): Pirfenidone
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AP01
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2021
AP01 was safe and well tolerated at both doses. Flu-like symptoms and GI adverse events most commonly attributed to oral pirfenidone were seen in less than 10% of patients treated with AP01.
Lead Product(s): RNA Engineered Allogeneic Human Mesenchymal Stem Cells
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Descartes-30
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 04, 2021
This $2 million competitive R&D award from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) will support Cartesian's clinical development for Descartes-30, the first RNA cell therapy for respiratory diseases.